Impact of HER2 low status on genomic signatures in triple negative breast cancer (TNBC)

被引：0
|
作者：
Taylor, Melissa
Reddy, Shilpa
Kumar, Prashanth Ashok
Hariri, Dana
Sokol, Ethan
Sivakumar, Smruthy
Quintanilha, Julia
Pavlick, Dean
Levy, Mia Alyce
Ross, Jeffrey S.
Lustberg, Maryam B.
机构：
[1] Yale New Haven Hosp, New Haven, CT USA
[2] Upstate Univ Hosp, Syracuse, NY USA
[3] SUNY Upstate Univ Hosp, Syracuse, NY USA
[4] Fdn Med Inc, Cambridge, MA USA
[5] Fdn Med Inc, Boston, MA USA
[6] Fdn Med, Cambridge, MA USA
[7] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1092
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Salivary expression of soluble HER2 in breast cancer patients with positive and negative HER2 status
    Laidi, Fatna
    Bouziane, Amal
    Lakhdar, Amina
    Khabouze, Samira
    Rhrab, Brahim
    Zaoui, Fatima
    ONCOTARGETS AND THERAPY, 2014, 7 : 1285 - 1289
  • [22] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    MODERN PATHOLOGY, 2016, 29 : 44A - 44A
  • [23] Impact of the Change of the Criteria for HER2 Immunohistochemistry Interpretation on HER2 Status in Breast Cancer
    Harada, Shuko
    Shen, Dejun
    Wei, Shi
    LABORATORY INVESTIGATION, 2016, 96 : 44A - 44A
  • [24] Evaluating Low HER2 Status in Breast Cancer Cases with Absent and Low HER2 Protein Expression
    Ardor, Gokce
    Komforti, Miglena
    Hanna, Helena
    Nassar, Aziza
    LABORATORY INVESTIGATION, 2023, 103 (03) : S94 - S95
  • [25] HER2 Mutation Status in Japanese HER2-negative Breast Cancer Patients
    Endo, Yumi
    Dong, Yu
    Yoshimoto, Nobuyasu
    Asano, Tomoko
    Hato, Yukari
    Yamashita, Hiroko
    Sato, Shinya
    Takahashi, Satoru
    Fujii, Yoshitaka
    Toyama, Tatsuya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2014, 44 (07) : 619 - 623
  • [26] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Nanae Horisawa
    Yayoi Adachi
    Daiki Takatsuka
    Kazuki Nozawa
    Yuka Endo
    Yuri Ozaki
    Kayoko Sugino
    Ayumi Kataoka
    Haruru Kotani
    Akiyo Yoshimura
    Masaya Hattori
    Masataka Sawaki
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 234 - 241
  • [27] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Horisawa, Nanae
    Adachi, Yayoi
    Takatsuka, Daiki
    Nozawa, Kazuki
    Endo, Yuka
    Ozaki, Yuri
    Sugino, Kayoko
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (02) : 234 - 241
  • [28] The 21-gene recurrence score and chemotherapy use in triple negative breast cancer (TNBC) and HER2 positive breast cancer: A National Cancer Database study
    Boughey, J. C.
    Hoskin, T. L.
    Cocco, D.
    Day, C. N.
    Leon-Ferre, R.
    Habermann, E. B.
    Goetz, M. P.
    CANCER RESEARCH, 2019, 79 (04)
  • [29] Response to neoadjuvant chemotherapy among women with triple-negative breast cancer by HER2 expression status
    Budhathoki, Pravash
    Shah, Anish
    Gaire, Suman
    Joshi, Utsav
    Yadav, Siddhartha
    CANCER RESEARCH, 2023, 83 (05)
  • [30] Prognostic Impact of HER2 Low Status in Male Breast Cancer: Prospective Cohort Analysis
    Ignatov, Atanas
    Lempfer, Sina
    Meszaros, Jozsef
    Eggemann, Holm
    CANCERS, 2024, 16 (19)
12345